Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 09:06:52 2024-04-23 pm EDT			5-day change	1st Jan Change
4,128 ^JPY	+0.15%		+1.60%	+1.68%

Apr. 22	Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	MT
Apr. 22	Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	CI

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY in Post-Transplant Recipients with Cytomegalovirus Infection

December 09, 2021 at 08:48 am EST

OSAKA - Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ('Takeda') today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY in post-transplant refractory(+) CMV infections with or without resistance(++) (R/R) were published in the journal of Clinical Infectious Diseases (CID).

The manuscript is available online and will be included in a future print edition of CID, the official peer-reviewed journal of the Infectious Diseases Society of America.1 The SOLSTICE study primary endpoint was met, with 55.7% (131/235) of adult patients on LIVTENCITY achieving confirmed CMV DNA level below the lower limit of quantification (

Latest news about Takeda Pharmaceutical Company Limited

Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy	Apr. 22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	Apr. 19	MT
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	Apr. 18	CI
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	Apr. 18	DJ
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	Apr. 15	MT
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	Mar. 31	CI
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder	Mar. 26	MT
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	Mar. 26	CI
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	Mar. 20	MT
Takeda Pharmaceutical Receives FDA Approval to Expand Iclusig's Indication in Blood Cancer Sub-Type	Mar. 19	MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	Mar. 19	MT
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® in Adult Patients with Newly Diagnosed Ph+ ALL	Mar. 19	CI
Takeda Pharmaceutical Says Mezagitamab Phase 2 Trial Shows 'Positive' Results in Primary Immune Thrombocytopenia Patients	Mar. 13	MT
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia	Mar. 13	CI
Toyota becomes Asia's most shorted large-cap stock - Hazeltree	Mar. 12	RE
India's Serum looks beyond COVID with new vaccines for malaria, dengue	Mar. 10	RE
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN
Takeda Pharmaceutical Teams Up With Biological E. to Boost Production of Dengue Vaccine	Feb. 27	MT
HEDGEFLOW - Japan enthusiasm driving inflows to US-listed Asian equities, Morgan Stanley says	Feb. 27	RE
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production	Feb. 27	RE
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas	Feb. 26	CI
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy	Feb. 13	MT

Chart Takeda Pharmaceutical Company Limited

Duration

Period

Chart Takeda Pharmaceutical Company Limited

More charts

Company Profile

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,122 JPY

Average target price

4,779 JPY

Spread / Average Target

+15.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+1.68%	41.85B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY in Post-Transplant Recipients with Cytomegalovirus Infection

EPS Revisions